Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

Abstract Background The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-direc...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Neil R. Parikh, Claudia Huiza, Jill S. Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P. Lee, Warren S. Inouye, Mark L. Jordan, Homayoon Sanati, Lida Jafari, Carol J. Bennett, Greg E. Gin, Amar U. Kishan, Robert E. Reiter, Michael Lewis, Ahmad Sadeghi, William J. Aronson, Isla P. Garraway, Matthew B. Rettig, Nicholas G. Nickols
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2019-04-01
Saila:	BMC Cancer
Gaiak:	Oligometastases Prostate cancer Stereotactic body radiotherapy Abiraterone Apalutamide Leuprolide
Sarrera elektronikoa:	http://link.springer.com/article/10.1186/s12885-019-5496-5
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!